pharmaphorum

OCTOBER 27, 2020

US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. Moreover, as an orally-active drug merimepodib could also have found a role outside the hospital setting.

Drug Trials 98

Drug Trials Trials Drugs Contract Manufacturing 98

pharmaphorum

JANUARY 6, 2021

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. Several others are in late-stage development, including fitusiran for haemophilia, which Sanofi is developing under license from Alnylam.

Gene Silencing 60

Gene Silencing Gene RNA Contract Manufacturing 60

The Pharma Data

NOVEMBER 17, 2021

Food and Drug Administration (FDA) includes clinical data from the Phase2/3 EPIC-HR ( Evaluation of Protease Inhibition for COVID-19 in High- Threat Cases) interim analysis. PF-07321332 inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication. This submission to theU.S.

HR 52

HR Manufacturing Contract Manufacturing Licensing 52

The Pharma Data

NOVEMBER 19, 2021

Food and Drug Administration (FDA). ” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication. Pfizer moment blazoned an agreement with theU.S.

HR 52

HR Contract Manufacturing Manufacturing Clinical Trials 52

The Pharma Data

MARCH 22, 2022

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

Drug Discovery World

SEPTEMBER 6, 2022

There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52